Literature DB >> 14638478

In vitro activity of daptomycin against vancomycin-resistant enterococci of various Van types and comparison of susceptibility testing methods.

James H Jorgensen1, Sharon A Crawford, Cynthia C Kelly, Jan E Patterson.   

Abstract

The increasing prevalence of vancomycin-resistant enterococcal (VRE) infections and the limited number of antimicrobial agents for their treatment emphasize a need for new, more effective agents. In this study, the in vitro activity of daptomycin was determined against a collection of 156 VRE from seven different institutions. Van types were characterized by PCR, and pulsed-field gel electrophoresis was performed to exclude isolates with >85% relatedness by dendrogram. Included were 126 Enterococcus faecium (109 vanA, 17 vanB) isolates, 5 Enterococcus faecalis (3 vanA, 2 vanB) isolates, 2 Enterococcus avium (vanA) isolates, 1 Enterococcus durans (vanA) isolate, 10 Enterococcus gallinarum (vanC1) isolates, and 12 Enterococcus casseliflavus (vanC2) isolates. MICs of daptomycin and five additional agents were determined by the NCCLS broth microdilution method with Mueller-Hinton (MH) broth containing supplemental calcium. MICs were also determined using two investigational E-test strip formulations, and disk diffusion testing was performed by the standard NCCLS method. The MIC of daptomycin at which 50% of the isolates tested were inhibited for this isolate collection was 4 microg/ml, and the MIC at which 90% of the isolates tested were inhibited was 8 microg/ml. Two isolates of vanA E. faecium were resistant to linezolid, and one isolate was resistant to quinupristin-dalfopristin. MICs of daptomycin determined by the E test with and without added calcium varied by 8- to 16-fold, and disk diffusion zones varied by 3 to 6 mm according to the calcium content of the commercial MH agar lots used in the study. This study has shown daptomycin to have good activity against a diverse collection of contemporary VRE isolates. However, improved standardization of the calcium content of MH agar will be important for reliable testing of daptomycin by clinical laboratories using either the E test or disk diffusion methods.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14638478      PMCID: PMC296189          DOI: 10.1128/AAC.47.12.3760-3763.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

Review 1.  Vancomycin-resistant enterococcal infections.

Authors:  B E Murray
Journal:  N Engl J Med       Date:  2000-03-09       Impact factor: 91.245

2.  In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers.

Authors:  A L Barry; P C Fuchs; S D Brown
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

3.  Detection of glycopeptide resistance genotypes and identification to the species level of clinically relevant enterococci by PCR.

Authors:  S Dutka-Malen; S Evers; P Courvalin
Journal:  J Clin Microbiol       Date:  1995-01       Impact factor: 5.948

4.  Emergence of increased resistance to quinupristin/dalfopristin during therapy for Enterococcus faecium bacteremia.

Authors:  J W Chow; S M Donahedian; M J Zervos
Journal:  Clin Infect Dis       Date:  1997-01       Impact factor: 9.079

5.  Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations.

Authors:  R L Akins; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

6.  Comparative In vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens.

Authors:  D R Snydman; N V Jacobus; L A McDermott; J R Lonks; J M Boyce
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

7.  Bactericidal activities of peptide antibiotics against multidrug-resistant Enterococcus faecium.

Authors:  N Mobarakai; J M Quale; D Landman
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

8.  Sequence of the vanB and ddl genes encoding D-alanine:D-lactate and D-alanine:D-alanine ligases in vancomycin-resistant Enterococcus faecalis V583.

Authors:  S Evers; P E Reynolds; P Courvalin
Journal:  Gene       Date:  1994-03-11       Impact factor: 3.688

9.  Characterization of glycopeptide-resistant enterococci from U.S. hospitals.

Authors:  N C Clark; R C Cooksey; B C Hill; J M Swenson; F C Tenover
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

Review 10.  Emergence of vancomycin-resistant enterococci.

Authors:  L B Rice
Journal:  Emerg Infect Dis       Date:  2001 Mar-Apr       Impact factor: 6.883

View more
  12 in total

1.  Correlation between mutations in liaFSR of Enterococcus faecium and MIC of daptomycin: revisiting daptomycin breakpoints.

Authors:  Jose M Munita; Diana Panesso; Lorena Diaz; Truc T Tran; Jinnethe Reyes; Audrey Wanger; Barbara E Murray; Cesar A Arias
Journal:  Antimicrob Agents Chemother       Date:  2012-06-04       Impact factor: 5.191

2.  Assessment of two commercial susceptibility test methods for determination of daptomycin MICs.

Authors:  James H Jorgensen; Sharon A Crawford
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

3.  In vitro synergy of daptomycin plus rifampin against Enterococcus faecium resistant to both linezolid and vancomycin.

Authors:  George Pankey; Deborah Ashcraft; Nalini Patel
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

4.  Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy.

Authors:  James S Lewis; Aaron Owens; Jose Cadena; Kathryn Sabol; Jan E Patterson; James H Jorgensen
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

5.  Clinical epidemiology of vancomycin-resistant Enterococcus gallinarum and Enterococcus casseliflavus bloodstream infections.

Authors:  Nicholas S Britt; Emily M Potter
Journal:  J Glob Antimicrob Resist       Date:  2015-12-21       Impact factor: 4.035

6.  Evaluating the Rapid Emergence of Daptomycin Resistance in Corynebacterium: a Multicenter Study.

Authors:  Kaitlin F Mitchell; Erin McElvania; Meghan A Wallace; Lauren E Droske; Amy E Robertson; Lars F Westblade; C A Burnham
Journal:  J Clin Microbiol       Date:  2021-03-19       Impact factor: 5.948

7.  Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding.

Authors:  Tiffanny Jones; Michael R Yeaman; George Sakoulas; Soo-Jin Yang; Richard A Proctor; Hans-Georg Sahl; Jacques Schrenzel; Yan Q Xiong; Arnold S Bayer
Journal:  Antimicrob Agents Chemother       Date:  2007-10-22       Impact factor: 5.191

Review 8.  A potential role for daptomycin in enterococcal infections: what is the evidence?

Authors:  Rafael Cantón; Patricia Ruiz-Garbajosa; Ricardo L Chaves; Alan P Johnson
Journal:  J Antimicrob Chemother       Date:  2010-04-02       Impact factor: 5.790

9.  In vitro activity of tigecycline against gram-positive and gram-negative pathogens as evaluated by broth microdilution and Etest.

Authors:  Chris M Pillar; Deborah C Draghi; Michael J Dowzicky; Daniel F Sahm
Journal:  J Clin Microbiol       Date:  2008-07-02       Impact factor: 5.948

Review 10.  Systematic review and meta-analysis of linezolid versus daptomycin for treatment of vancomycin-resistant enterococcal bacteremia.

Authors:  Eleni P Balli; Chris A Venetis; Spiros Miyakis
Journal:  Antimicrob Agents Chemother       Date:  2013-11-18       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.